Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Nkarta, Inc. (NASDAQ:NKTX - Get Free Report) have been given a consensus recommendation of "Buy" by the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $14.86.

Several equities analysts recently commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Nkarta in a research note on Wednesday, April 9th. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Nkarta in a report on Thursday, March 27th. Finally, Stifel Nicolaus cut their price objective on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 27th.

Nkarta Trading Down 6.1 %

NASDAQ NKTX traded down $0.14 on Monday, hitting $2.07. 150,083 shares of the company's stock were exchanged, compared to its average volume of 1,094,680. Nkarta has a 52 week low of $1.31 and a 52 week high of $8.33. The stock has a 50-day moving average of $1.77 and a 200-day moving average of $2.42. The stock has a market cap of $146.53 million, a price-to-earnings ratio of -1.10 and a beta of 0.83.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.06. As a group, analysts predict that Nkarta will post -1.7 earnings per share for the current year.

Institutional Trading of Nkarta

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its position in shares of Nkarta by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 31,056 shares of the company's stock valued at $77,000 after buying an additional 6,763 shares during the last quarter. Catalina Capital Group LLC boosted its holdings in Nkarta by 57.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock valued at $47,000 after acquiring an additional 6,867 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Nkarta by 41.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock valued at $60,000 after purchasing an additional 7,030 shares during the period. American Century Companies Inc. increased its position in Nkarta by 8.8% during the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock valued at $226,000 after purchasing an additional 7,378 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Nkarta by 4.1% during the 4th quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock worth $561,000 after purchasing an additional 8,883 shares during the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.